WallStreetZenWallStreetZen

NASDAQ: ATYR
Atyr Pharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for ATYR

Based on 2 analysts offering 12 month price targets for Atyr Pharma Inc.
Min Forecast
$16.00+760.22%
Avg Forecast
$25.50+1,270.97%
Max Forecast
$35.00+1,781.72%

Should I buy or sell ATYR stock?

Based on 2 analysts offering ratings for Atyr Pharma Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ATYR stock forecasts and price targets.

ATYR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-07-22
lockedlocked$00.00+00.00%2024-03-15

1 of 1

Forecast return on equity

Is ATYR forecast to generate an efficient return?
Company
62.09%
Industry
71.46%
Market
80.46%
ATYR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ATYR forecast to generate an efficient return on assets?
Company
46.31%
Industry
30.8%
ATYR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ATYR earnings per share forecast

What is ATYR's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.89
Avg 2 year Forecast
-$0.74
Avg 3 year Forecast
$0.27

ATYR revenue forecast

What is ATYR's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$367.0k-37.59%
Avg 2 year Forecast
$12.6M+2,042.86%
Avg 3 year Forecast
$95.3M+16,115.14%
ATYR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ATYR revenue growth forecast

How is ATYR forecast to perform vs Biotechnology companies and vs the US market?
Company
431.52%
Industry
64.18%
Market
11.31%
ATYR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ATYR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ATYR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATYR$1.86$25.50+1,270.97%Buy
TVGN$0.77N/AN/A
CRVO$15.32$66.00+330.81%Strong Buy
FGEN$1.26N/AN/A
IMUX$1.46$19.00+1,201.37%Strong Buy

Atyr Pharma Stock Forecast FAQ

Is Atyr Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ATYR) stock is to Buy ATYR stock.

Out of 2 analysts, 0 (0%) are recommending ATYR as a Strong Buy, 2 (100%) are recommending ATYR as a Buy, 0 (0%) are recommending ATYR as a Hold, 0 (0%) are recommending ATYR as a Sell, and 0 (0%) are recommending ATYR as a Strong Sell.

If you're new to stock investing, here's how to buy Atyr Pharma stock.

What is ATYR's earnings growth forecast for 2024-2026?

(NASDAQ: ATYR) Atyr Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.64%.

Atyr Pharma's earnings in 2024 is -$53,929,000.On average, 2 Wall Street analysts forecast ATYR's earnings for 2024 to be -$61,419,737, with the lowest ATYR earnings forecast at -$69,701,049, and the highest ATYR earnings forecast at -$53,138,424. On average, 2 Wall Street analysts forecast ATYR's earnings for 2025 to be -$51,068,096, with the lowest ATYR earnings forecast at -$66,940,612, and the highest ATYR earnings forecast at -$35,195,579.

In 2026, ATYR is forecast to generate $18,632,954 in earnings, with the lowest earnings forecast at -$8,281,313 and the highest earnings forecast at $45,547,220.

What is ATYR's revenue growth forecast for 2024-2026?

(NASDAQ: ATYR) Atyr Pharma's forecast annual revenue growth rate of 431.52% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.18%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.31%.

Atyr Pharma's revenue in 2024 is $588,000.On average, 2 Wall Street analysts forecast ATYR's revenue for 2024 to be $25,327,015, with the lowest ATYR revenue forecast at $16,217,571, and the highest ATYR revenue forecast at $34,505,470. On average, 1 Wall Street analysts forecast ATYR's revenue for 2025 to be $869,537,844, with the lowest ATYR revenue forecast at $869,537,844, and the highest ATYR revenue forecast at $869,537,844.

In 2026, ATYR is forecast to generate $6,579,848,074 in revenue, with the lowest revenue forecast at $1,862,605,271 and the highest revenue forecast at $11,297,090,878.

What is ATYR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ATYR) forecast ROA is 46.31%, which is higher than the forecast US Biotechnology industry average of 30.8%.

What is ATYR's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ATYR price target, the average ATYR price target is $25.50, with the highest ATYR stock price forecast at $35.00 and the lowest ATYR stock price forecast at $16.00.

On average, Wall Street analysts predict that Atyr Pharma's share price could reach $25.50 by Jul 22, 2025. The average Atyr Pharma stock price prediction forecasts a potential upside of 1,270.97% from the current ATYR share price of $1.86.

What is ATYR's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: ATYR) Atyr Pharma's current Earnings Per Share (EPS) is -$0.90. On average, analysts forecast that ATYR's EPS will be -$0.89 for 2024, with the lowest EPS forecast at -$1.01, and the highest EPS forecast at -$0.77. On average, analysts forecast that ATYR's EPS will be -$0.74 for 2025, with the lowest EPS forecast at -$0.97, and the highest EPS forecast at -$0.51. In 2026, ATYR's EPS is forecast to hit $0.27 (min: -$0.12, max: $0.66).

What is ATYR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ATYR) forecast ROE is 62.09%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.